DI 23022.865:
Pelizaeus-Merzbacher Disease--Connatal Form
Effective Dates: 08/10/2012 - Present- Effective Dates: 03/28/2018 - Present
TN 7 (08-12)- TN 16 (03-18)
- DI 23022.865 Pelizaeus-Merzbacher Disease--Connatal Form
- COMPASSIONATE ALLOWANCE INFORMATION
- PELIZAEUS-MERZBACHER DISEASE--CONNATAL FORM
ALTERNATE NAMES- ALTERNATE NAMES
- Connatal Pelizaeus-Merzbacher Disesase; Connatal PMD; Cockayane-Pelizaeus-Merzbacher Disease; Type II Connatal Pelizaeus-Merzbacher Disease; Severe PMD
DESCRIPTION- DESCRIPTION
- Pelizaeus-Merzbacher Disease (PMD) is a rare, neurodegenerative disorder and is one of a group of genetic disorders called leukodystrophies affecting the white matter of the brain and spinal cord. There are two main types of PMD: Classic PMD (see Classic PMD template) and Connatal PMD. Pelizaeus-Merzbacher Disease - Connatal Form (Connatal PMD) is the most severe, with profound motor and cognitive developmental delays. Symptoms begin shortly after birth with muscle weakness, abnormal eye movements, respiratory distress, feeding difficulties, and seizures. As the child ages, developmental delays become more obvious. Other features include progressive muscle spasticity leading to joint deformities, lack of coordination, and seizures. Older children are generally nonverbal and non-ambulatory.
DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM CODING- DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM CODING
- Diagnostic testing: MRI demonstrates symmetric and widespread abnormality of the white matter of the cerebrum, brain stem, and cerebellum.
- Physical findings: Individuals with Connatal PMD have poor growth, microcephaly, joint contractures, ataxia, generalized hypotonia, and nystagmus.
- ICD-9: 330.0
ONSET AND PROGRESSION- ONSET AND PROGRESSION
- Connatal PMD presents in the first month of life and is often fatal during the first decade of life, typically due to respiratory complications.
TREATMENT- TREATMENT
- There is no cure for PMD, and treatment is supportive and symptom specific. Physical and occupational therapies are used to minimize joint contractures and dislocations. Tracheostomy may be necessary for pharyngeal weakness. Medications are prescribed for seizures and movement disorders.
SUGGESTED PROGRAMMATIC ASSESSMENT*- SUGGESTED PROGRAMMATIC ASSESSMENT*
Suggested MER for evaluation:- Suggested MER for evaluation:
- * Clinical history and examination that describes the diagnostic features of the impairment
- * MRI of the brain showing abnormal white matter (demyelination)
Suggested Listings for Evaluation:- Suggested Listings for Evaluation:
DETERMINATION- DETERMINATION
- LISTING
REMARKS- Meets Listing
Meets Listing- 110.08
110.08 B111.06 A or B - 111.06
Medical Equals- Medical Equals
-
* Adjudicators may, at their discretion, use the Medical Evidence of Record or Listings suggested to evaluate the claim. However, the decision to allow or deny the claim rests with the adjudicator.- * Adjudicators may, at their discretion, use the Medical Evidence of Record or Listings suggested to evaluate the claim. However, the decision to allow or deny the claim rests with the adjudicator.
x
← This means that the line
was removed and
was added – in other words, the "Effective Dates" line at the top of the document has been updated to reflect that the new version is effective as of the date the change was made.